Search by Drug Name or NDC
NDC 00173-0869-61 Anoro Ellipta 62.5; 25 ug/1; ug/1 Details
Anoro Ellipta 62.5; 25 ug/1; ug/1
Anoro Ellipta is a RESPIRATORY (INHALATION) POWDER in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by GlaxoSmithKline LLC. The primary component is UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE.
MedlinePlus Drug Summary
The combination of umeclidinium and vilanterol is used to control wheezing, shortness of breath, coughing, and chest tightness caused by chronic obstructive pulmonary disease (COPD; a group of diseases that affect the lungs and airways, which includes chronic bronchitis and emphysema). Umeclidinium is in a class of medications called anticholinergics. Vilanterol is in a class of medications called long-acting beta-agonists (LABAs). These medications work by relaxing and opening air passages in the lungs, making it easier to breathe.
Related Packages: 00173-0869-61Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Umeclidinium and Vilanterol Oral Inhalation
Product Information
| NDC | 00173-0869 |
|---|---|
| Product ID | 0173-0869_99500bf8-e1f7-4aff-8f8e-4d4d1a54fea0 |
| Associated GPIs | 44209902958020 |
| GCN Sequence Number | 071883 |
| GCN Sequence Number Description | umeclidinium brm/vilanterol tr BLST W/DEV 62.5-25MCG INHALATION |
| HIC3 | B62 |
| HIC3 Description | BETA-ADRENERGIC AND ANTICHOLINERGIC COMBO, INHALED |
| GCN | 35903 |
| HICL Sequence Number | 040852 |
| HICL Sequence Number Description | UMECLIDINIUM BROMIDE/VILANTEROL TRIFENATATE |
| Brand/Generic | Brand |
| Proprietary Name | Anoro Ellipta |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | umeclidinium bromide and vilanterol trifenatate |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | POWDER |
| Route | RESPIRATORY (INHALATION) |
| Active Ingredient Strength | 62.5; 25 |
| Active Ingredient Units | ug/1; ug/1 |
| Substance Name | UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE |
| Labeler Name | GlaxoSmithKline LLC |
| Pharmaceutical Class | Adrenergic beta2-Agonists [MoA], Anticholinergic [EPC], Cholinergic Antagonists [MoA], beta2-Adrenergic Agonist [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA203975 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00173-0869-61 (00173086961)
| NDC Package Code | 0173-0869-61 |
|---|---|
| Billing NDC | 00173086961 |
| Package | 1 TRAY in 1 CARTON (0173-0869-61) / 1 INHALER in 1 TRAY / 7 POWDER in 1 INHALER |
| Marketing Start Date | 2014-01-31 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |